| Literature DB >> 28877681 |
Misaki Takii1, Takaichi Suehiro2,3, Aya Shima1, Hideki Yotsueda1, Satoshi Hisano4, Ritsuko Katafuchi5.
Abstract
BACKGROUND: Fibronectin glomerulopathy is a rare, inherited, autosomal dominant, glomerular disease characterized by proteinuria, microscopic hematuria, hypertension, massive glomerular deposits of fibronectin, and slow progression to end-stage renal failure. Because the incident of fibronectin glomerulopathy is extremely low, the pathophysiology, genetic abnormalities, epidemiology, and mechanisms remain to be elucidated. CASEEntities:
Keywords: Congenital esophageal atresia; Fibronectin 1 gene; Fibronectin glomerulopathy; Persistent cloaca
Mesh:
Year: 2017 PMID: 28877681 PMCID: PMC5588616 DOI: 10.1186/s12882-017-0704-5
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Light and electron microscopic images of kidney biopsy sections. a Periodic acid-Schiff (PAS) stain. A glomerulus showing mesangial hypercellularity and increased in PAS-positive materials in the mesangium. Original magnification, ×400. b Periodic acid-methenamine-silver stain. Increased materials in the mesangium were negative for methenamine-silver staining. Original magnification, ×200. c, d Electron microscopy showed diffuse granular deposits in the mesangium and the subepithelial spaces of the glomerular basement membrane. Original magnification, ×4000 (c) and ×10,000 (d)
Fig. 2Immunofluorescent staining. Immunofluorescent staining revealed slight staining for fibrinogen (d), but no staining for IgG, IgA, IgM, kappa light chain and lambda light chain (a-c, e, f)
Fig. 3Immunohistochemical staining for fibronectin. a Staining with IST-4 showed a positive mesangial pattern. b Staining with IST-9 was negative
Clinical characteristics of the 75 reported cases of fibronectin glomerulopathy
| Age | Sex | UP | Cre | Comorbidity | Family history | FN1 mutation | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Strøm et al. | 59 | F | 3.9 | 1.0 | NA | + | NA |
| 2 | 18 | M | 4.5 | 1.2 | NA | + | NA | |
| 3 | 24 | M | 14.0 | 1.0 | NA | + | NA | |
| 4 | 21 | M | 2–4 | 1.0 | NA | + | NA | |
| 5 | 19 | M | NA | NA | NA | + | NA | |
| 6 | 22 | F | NA | NA | NA | + | NA | |
| 7 | 25 | F | 5.0 | NA | NA | + | NA | |
| 8 | 14 | F | NS | 0.6 | NA | + | NA | |
| 9 | 64 | M | 2.0 | 1.1 | NA | + | NA | |
| 10 | 16 | M | 5.0 | NA | NA | + | NA | |
| 11 | 23 | M | 0.6 | 0.8 | NA | + | NA | |
| 12 | 25 | F | 0.3 | 0.8 | NA | + | NA | |
| 13 | 30 | M | 2.1 | 1.3 | NA | + | NA | |
| 14 | 24 | M | 1.3 | 1.4 | NA | + | NA | |
| 15 | 26 | F | + | NA | cerebrovascular hemorrhage | + | NA | |
| 16 | 29 | M | 3+ | 1.8 | cerebrovascular hemorrhage | + | NA | |
| 17 | 15 | M | 4+ | NA | cerebrovascular hemorrhage | + | NA | |
| 18 | 14 | M | 3+ | 0.8 | NA | + | NA | |
| 19 | 44 | M | 4.7 | 1.6 | NA | + | NA | |
| 20 | 37 | F | 0.7 | 0.9 | NA | + | NA | |
| 21 | 33 | M | 1.0 | 1.0 | NA | + | NA | |
| 22 | 31 | M | 2.1 | 1.0 | NA | + | NA | |
| 23 | 53 | M | NS | NA | renal cell carcinoma | + | NA | |
| 24 | Gemperle et al. | 35 | F | 5.6 | NA | NA | + | NA |
| 25 | 31 | M | 1.8 | NA | myocardial infarction | + | NA | |
| 26 | 38 | M | + | NA | NA | + | NA | |
| 27 | 46 | F | 0.1 | NA | NA | + | NA | |
| 28 | 42 | M | + | NA | renal cell carcinoma | + | NA | |
| 29 | 30 | M | 0.5 | NA | myocardial infarction | + | NA | |
| 30 | 33 | F | 0.7 | NA | NA | + | NA | |
| 31 | 32 | M | 1.0 | NA | myocardial infarction | + | NA | |
| 32 | 20 | M | + | NA | NA | + | NA | |
| 33 | Sato et al. | 23 | M | 2.0 | 0.9 | NA | + | NA |
| 34 | Uesugi et al. | 4 | M | 8.0 | 0.2 | NA | + | NA |
| 35 | 19 | F | 7.0 | 0.6 | NA | NA | NA | |
| 36 | 27 | M | 1.0 | 0.8 | NA | + | NA | |
| 37 | 58 | M | 12.0 | 1.6 | NA | + | NA | |
| 38 | 75 | M | 2.1 | NA | NA | + | NA | |
| 39 | Niimi et al. | 3 | M | 8.0 | 0.2 | NA | + | NA |
| 40 | Castelletti et al. | 59 | F | NS | Nomal | NA | + | + |
| 41 | 44 | M | 0.3 | 1.4 | NA | + | + | |
| 42 | 40 | M | NA | 2.2 | NA | + | + | |
| 43 | 35 | M | NS | 1.5 | NA | + | + | |
| 44 | 18 | M | 4.2 | 1.4 | NA | + | + | |
| 45 | 27 | M | 0.7 | 0.8 | NA | + | + | |
| 46 | 16 | M | NA | Nomal | NA | + | + | |
| 47 | 12 | M | 7.5 | 0.7 | NA | + | + | |
| 48 | Yong et al. | 41 | M | NS | 1.7 | NA | + | NA |
| 49 | Nadamuni et al. | 50 | F | 4.8 | 0.8 | anxiety, depression | + | + |
| 50 | Otsuka et al. | 52 | F | 0.4 | 1.5 | atrial septal defect | − | NA |
| 51 | Yoshino et al. | 67 | M | 3.6 | 1.7 | thymic carcinoid | − | NA |
| 52 | Baydar et al. | 24 | M | 1.0 | 0.8 | asthma | + | + |
| 53 | Ishimoto et al. | 78 | F | 10.2 | 1.1 | NA | − | − |
| 54 | Chen et al. | 34 | F | 3.6 | 0.7 | NA | − | NA |
| 55 | 24 | M | 3.9 | 2.0 | NA | − | NA | |
| 56 | 46 | M | 3.7 | 0.8 | NA | + | NA | |
| 57 | 32 | M | 1.2 | 0.9 | NA | − | NA | |
| 58 | 27 | F | 3.8 | 0.5 | NA | − | NA | |
| 59 | 26 | M | 7.4 | 1.5 | NA | − | NA | |
| 60 | 19 | M | 9.1 | 1.4 | NA | − | NA | |
| 61 | 32 | F | 9.1 | 3.4 | NA | − | NA | |
| 62 | 29 | M | 7.0 | 1.5 | NA | − | NA | |
| 63 | 19 | F | 2.8 | 0.6 | NA | − | NA | |
| 64 | Ohtsubo et al. | 20 | M | 0.86 | 92.1a | NA | + | + |
| 65 | 13 | F | 1.6 | 115a | NA | − | + | |
| 66 | 35 | F | ESRD | ESRD | NA | + | + | |
| 67 | 54 | F | ESRD | ESRD | NA | + | + | |
| 68 | 35 | F | 5.85 | 76.3a | NA | − | + | |
| 69 | 15 | F | 0.51 | 86.5a | NA | + | + | |
| 70 | 53 | F | 11.8 | 48a | NA | − | + | |
| 71 | 16 | M | 0.44 | 124.1a | NA | − | + | |
| 72 | 74 | M | 3.56 | 63a | NA | − | + | |
| 73 | 38 | F | 4.9 | 55.3a | NA | + | + | |
| 74 | 14 | F | 10.1 | 123.4a | NA | − | + | |
| 75 | 64 | M | 4.6 | 46.3a | NA | − | + | |
| 76 | This case | 21 | F | 3.4 | 0.7 | persistent cloaca | − | − |
F female, M male, UP urinary protein (g/24 h), Cre creatinine (mg/dl), NA not available, NS nephrotic syndrome, ESRD end-stage renal disease
aeGFR (ml/min/1.73 m2)